Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WINDLAS BIOTECH Plunges 15%; BSE HEALTHCARE Index Down 0.0%
Tue, 13 Aug 14:54

WINDLAS BIOTECH Plunges 15%; BSE HEALTHCARE Index Down 0.0%Image source: peterschreiber.media/www.istockphoto.com

WINDLAS BIOTECH share price has plunged 15% and is presently trading at Rs 740.2.

Meanwhile, the BSE HEALTHCARE index is at 41,030.5 .

Among the top losers in the BSE HEALTHCARE index today are Cadila Healthcare (down 5.6%) and ALEMBIC PHARMA (down 3.1%).

FORTIS HEALTHCARE (up 3.5%) and Aurobindo Pharma (up 3.3%) are among the top gainers today.

Over the last one year, WINDLAS BIOTECH has moved up from Rs 347.1 to Rs 740.2, registering a gain of Rs 393.1 (up 113.3%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,485.8 to 41,030.5, registering a gain of 44.0% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 110.8%), Jubilant Pharmova (up 110.0%) and SUVEN PHARMACEUTICALS (up 103.2%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 78,946.8 (down 0.9%).

The top losers among the BSE Sensex today are HDFC Bank (down 3.3%) and Tata Motors (down 2.2%). The most traded stocks in the BSE Sensex are Reliance Ind. and Tata Steel.

In the meantime, NSE Nifty is at 24,131.7 (down 0.9%). BPCL and HDFC Bank are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,995.8 to 78,946.8, registering a gain of 12,951.0 points (up 19.6%).

WINDLAS BIOTECH Financial Update...

WINDLAS BIOTECH net profit grew 48.5% YoY to Rs 170 million for the quarter ended March 2024, compared to a profit of Rs 114 million a year ago. Net sales rose 21.7% to Rs 1,713 million during the period as against Rs 1,407 million in January-March 2023.

For the year ended March 2023, WINDLAS BIOTECH reported 11.9% increase in net profit to Rs 426 million compared to net profit of Rs 381 million during FY22. Revenue of the company grew 10.1% to Rs 5,131 million during FY23.

The current Price to earnings ratio of WINDLAS BIOTECH, based on rolling 12 month earnings, stands at 26.6.


Equitymaster requests your view! Post a comment on "WINDLAS BIOTECH Plunges 15%; BSE HEALTHCARE Index Down 0.0%". Click here!